湖南省人民医院(湖南师范大学附属第一医院)
Hunan Provincial People's Hospital
在本站收录的 53 种疾病中,这家医院列在其中 11 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
湖南省人民医院(湖南师范大学附属第一医院)的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma1 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma50 篇牵头论文
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 骨肉瘤Osteosarcoma12 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
- 神经母细胞瘤Neuroblastoma2 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
- IgA 肾病IgA nephropathy1 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
未列出的收录疾病:食管鳞状细胞癌、胃癌、脊索瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 50 篇,占 0.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
长沙有 6 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- 分期
- I期
- 开始
- 2023-10
- 登记号
- NCT06560827
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙
- 正在招募Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2022-07
- 登记号
- NCT05444478
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文50
- Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: a meta-analysis.
- Metabolic dynamics and stage-specific biomarkers in chronic HBV infection: a metabolomics study.
- The impact of ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation (MWA) and standard MWA on the local tumor progression of hepatocellular carcinoma with unclear ultrasound images.
- Integration of Meta-Analysis and Network Pharmacology to Investigate the Pharmacological Mechanisms of Quercetin on Hepatocellular Carcinoma.
- PA/MR imaging-guided precision phototherapy and efficacy evaluation of hepatocellular carcinoma utilizing a targeted multifunctional nanoprobe.
- The role of tumor-associated endothelial cells in malignant progression and immune evasion of liver cancer.
- Drug repurposing: isosorbide mononitrate enhances tumor accumulation to augment sonodynamic therapy for hepatocellular carcinoma.
- CircERBB3 Targets miR-194-5p/PRMT3 to Promote Hepatocellular Carcinoma Progression.
- LncRNA FGD5-AS1 Facilitates Hepatocellular Carcinoma Cell Stemness by Enhancing PKD1 mRNA Stability Through Binding With MSI2.
- Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).
- Anemarchalconyn, a natural alkyne ketone compound, inhibits HCC cell growth by suppressing Polθ and inducing synthetic lethality in Homologous recombination deficiency cells.
- Lymphoepithelioma-like cholangiocarcinoma mimicking hepatocellular carcinoma.
- Evaluation of genetic instability of short tandem repeats in hepatocellular carcinoma.
- STC2 knockdown inhibits cell proliferation and glycolysis in hepatocellular carcinoma through promoting autophagy by PI3K/Akt/mTOR pathway.
- Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.
- Potential role of predictive models in assessment of liver inflammation in patients with hepatocellular carcinoma: a two-center cohort study.
- Obovatol inhibits proliferation, invasion and immune escape of hepatocellular carcinoma cells through modulating the JAK/STST3/PD-L1 pathway.
- Potential Influence of Inconsistent Arterial Phase Imaging on Macrotrabecular-massive Hepatocellular Carcinoma Prediction.
- FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production.
- Network-based pharmacology-based research on the effect and mechanism of the Hedyotis diffusa-Scutellaria Barbata pair in the treatment of hepatocellular carcinoma.
- CSNK2A2 promotes hepatocellular carcinoma progression through activation of NF-κB pathway.
- A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing.
- S100A family is a group of immune markers associated with poor prognosis and immune cell infiltration in hepatocellular carcinoma.
- ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
- ZNF655 promotes the progression of hepatocellular carcinoma through PSMB8.
- Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.
- Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.
- Hepatic Inflammatory Pseudotumor-like Follicular Dendritic Cell Sarcoma Mimicking Hepatocellular Carcinoma.
- miR-3682-3p Activated by c-Myc Aggravates the Migration and Stemness in Hepatocellular Carcinoma Cells by Regulating PTEN/PI3K/AKT/β-Catenin Signaling.
- Full laparoscopic anatomical liver segment VII resection with preferred Glissonean pedicle and dorsal hepatic approach.
- Vascular endothelial growth factor A is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
- Genetic variants only improve hepatocellular carcinoma risk stratification in patients with alcohol-related cirrhosis?
- Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study.
- The Influence of Single Arterial Phase Imaging on Prediction of Microvascular Invasion of Hepatocellular Carcinoma.
- METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
- Adjuvant transarterial chemoembolization for intermediate-stage hepatocellular carcinoma with microvascular invasion.
- Association of hypoxia-inducible factor 1α expression with susceptibility to hepatitis B virus-related hepatocellular carcinoma: A meta-analysis.
- Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
- SOX9/MKLN1-AS Axis Induces Hepatocellular Carcinoma Proliferation and Epithelial-Mesenchymal Transition.
- The Application Value of MRI T2∗WI Radiomics Nomogram in Discriminating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma.
- Verbascoside enhances radiosensitivity of hepatocellular carcinoma cells through regulating miR-101-3p/Wee1 axis.
- Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
- Long noncoding RNA LINC01419 promotes hepatocellular carcinoma malignancy by mediating miR-485-5p/LSM4 axis.
- A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.
- PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
- Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
- miR-660-5p-loaded M2 macrophages-derived exosomes augment hepatocellular carcinoma development through regulating KLF3.
- Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
- Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
- Prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm based on computed tomography radiomics.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
- TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
- Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 6 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 10 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文12
- Signatures of tumor microenvironment-related genes and long noncoding RNAs predict poor prognosis in osteosarcoma.
- Advances in drug resistance of osteosarcoma caused by pregnane X receptor.
- TCF12 Transcriptionally Activates SPHK1 to Induce Osteosarcoma Angiogenesis by Promoting the S1P/S1PR4/STAT3 Axis.
- The immune cell infiltration-associated molecular subtypes and gene signature predict prognosis for osteosarcoma patients.
- Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.
- Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.
- Primary hepatic fibroblastic osteosarcoma with the comorbidity of sigmoid adenocarcinoma.
- LncRNA HCG18 Promotes Osteosarcoma Cells Proliferation, Migration, and Invasion in by Regulating miR-34a/RUNX2 Pathway.
- Identification of an EMT-related gene-based prognostic signature in osteosarcoma.
- LncRNA KIAA0087 suppresses the progression of osteosarcoma by mediating the SOCS1/JAK2/STAT3 signaling pathway.
- CircKIF4A enhances osteosarcoma proliferation and metastasis by sponging MiR-515-5p and upregulating SLC7A11.
- The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress.
早期论文(2016–2020 年)5
- Diallyl trisulfide regulates cell apoptosis and invasion in human osteosarcoma U2OS cells through regulating PI3K/AKT/GSK3β signaling pathway.
- Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma.
- LncRNA LINC00210 regulated radiosensitivity of osteosarcoma cells via miR-342-3p/GFRA1 axis.
- LncRNA SNHG10 increases the methylation of miR-218 gene to promote glucose uptake and cell proliferation in osteosarcoma.
- CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 3 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)1
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 6 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文3
- Shared genetic architecture and potential comorbid mechanisms between rheumatoid arthritis and idiopathic pulmonary fibrosis.
- m6A methyltransferase ZC3H13 improves pulmonary fibrosis in mice through regulating Bax expression.
- miR-184 targets TP63 to block idiopathic pulmonary fibrosis by inhibiting proliferation and epithelial-mesenchymal transition of airway epithelial cells.
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 7 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文1
早期论文(2016–2020 年)3
- Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study.
- The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model.
- Indoleamine 2,3-Dioxygenase (IDO) Regulates Th17/Treg Immunity in Experimental IgA Nephropathy.
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
长沙有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
联系这家医院
出示给工作人员或司机的院名卡
湖南省人民医院(湖南师范大学附属第一医院)
Hunan Provincial People's Hospital
长沙
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药